Initiation of study marks an important milestone in advancing Neurocrine’s obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
